---
title: "SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 43.36 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252844159.md"
datetime: "2025-08-13T11:12:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252844159.md)
  - [en](https://longbridge.com/en/news/252844159.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252844159.md)
generator: "portal-rs"
---

# SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 43.36 M

Revenue: As of FY2025 Q2, the actual value is USD 43.36 M.

EPS: As of FY2025 Q2, the actual value is USD 0.02.

EBIT: As of FY2025 Q2, the actual value is USD 13.54 M.

### Segment Revenue

-   **Franchising Revenue**: $10,007,581 for Q2 2025, a decrease of 31.58% from $14,626,256 in Q2 2024.
-   **Procurement Revenue**: $15,756,519 for Q2 2025, an increase of 16.40% from $13,536,608 in Q2 2024.
-   **Management Services Revenue**: $5,138,578 for Q2 2025, a decrease of 69.24% from $16,705,597 in Q2 2024.
-   **Rental Services Revenue**: $6,851,176 for Q2 2025, an increase of 98.40% from $3,453,173 in Q2 2024.
-   **Other Revenues**: $5,604,993 for Q2 2025, an increase of 17.25% from $4,780,446 in Q2 2024.

### Operational Metrics

-   **Net Income**: $2,439,852 for Q2 2025, a decrease of 86.85% from $18,557,325 in Q2 2024.
-   **Gross Profit**: $30,010,577 for Q2 2025, a decrease of 23.87% from $39,419,675 in Q2 2024.
-   **Operating Expenses**: $15,456,385 for Q2 2025, an increase of 27.43% from $12,129,115 in Q2 2024.
-   **Income from Operations**: $14,554,192 for Q2 2025, a decrease of 46.67% from $27,290,560 in Q2 2024.
-   **Income Tax Expense**: $11,100,509 for Q2 2025, an increase of 30.15% from $8,529,110 in Q2 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: -$6,411,168 for the six months ended June 30, 2025, compared to $22,874,760 provided by operating activities for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: $15,397,998 for the six months ended June 30, 2025, compared to -$9,405,716 used in investing activities for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $6,901,719 for the six months ended June 30, 2025, compared to -$109,341 used in financing activities for the same period in 2024.

### Unique Metrics

-   **Change in Fair Value of Cryptocurrencies**: $111,632 for Q2 2025, compared to nil for Q2 2024.
-   **Gain on Redemption of Life Insurance Policies**: $8,746,138 for the six months ended June 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to maintain and strengthen its market position and brand in the cosmetic medical treatment management market in Japan, Vietnam, and Singapore, and grow its presence globally.
-   **Non-Core Business**: The company completed the disposal of its subsidiaries, Kijimadairakanko Inc. and Skynet Academy Co., Ltd., in December 2024.
-   **Priority**: The company expects to deploy capital for investment opportunities that align with its growth strategy, selectively pursuing prospects in the expanding global medical aesthetics market.

### Related Stocks

- [SBCWW.US](https://longbridge.com/en/quote/SBCWW.US.md)

## Related News & Research

- [Tyra Bioscience Director Makes Bold Insider Move That Could Signal Big Things Ahead](https://longbridge.com/en/news/298782816.md)
- [Reliance (RS) Heads To Jefferies Conference Following Demand Led Fair Value Debate](https://longbridge.com/en/news/298815052.md)
- [Estée Lauder Companies (EL) Leadership Reset Puts Its Valuation Narrative To The Test](https://longbridge.com/en/news/298814962.md)
- [What Callaway Golf Stock's Weak Demand Means For Shareholders](https://longbridge.com/en/news/298808210.md)
- [Can PBF Energy (PBF) Justify Its Price Following Blowout Earnings And A New Dividend?](https://longbridge.com/en/news/298807882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**